CDC Weekly Flu Update - Week 41

Week ending in October 13, 2018
Last Updated October 22, 2018

ILI = 1.4

Influenza-Like Illness (ILI) Activity Geography Map

Summary of Influenza Activities

Viral Surveillance: Influenza A viruses have predominated in the United States since the beginning of July. The percentage of respiratory specimens testing positive for influenza in clinical laboratories was low.

  • Virus Characterization: The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.
  • Antiviral Resistance: All viruses tested since late May show susceptibility to the antiviral drugs oseltamivir, zanamivir, and peramivir.

Influenza-like Illness Surveillance: The proportion of outpatient visits for influenza-like illness (ILI) remained low at 1.4%, which is below the national baseline of 2.2%. All regions reported ILI below their region-specific baseline level.

ILI State Activity Indictor Map: New York City, the District of Columbia, and 49 states experienced minimal ILI activity, and Puerto Rico and one state had insufficient data.

Geographic Spread of Influenza: The geographic spread of influenza in Guam and two states was reported as local activity; the District of Columbia, the U.S. Virgin Islands and 40 states reported sporadic activity; eight states reported no activity; and Puerto Rico did not report.

Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

Influenza-associated Pediatric Deaths: One influenza-associated pediatric death that occurred during the 2018-2019 season was reported to CDC.

The graphs and summary in this section are based on information available from the Weekly U.S. Influenza Surveillance Report found on the CDC website.

Laboratory

What could you do with the RIGHT workflow?

Near patient testing reduces collect-to-result time by 70%1

1. Hernandez D, et al. Near Point-of-Care Adoption of Molecular FluA-B/RSV Testing within an Integrated Healthcare Delivery Network. Poster Presented at ASM Clinical Virology Symposium. 2018 May 6. West Palm Spring, Florida, USA.

Emergency Department

What could you accomplish with reliable results RIGHT now?


18% Fewer Tests Performed1-3


17% Fewer Antibiotics Prescribed1-3


$200-$699 ED Savings per Patient Visit1-3

1. Hansen GT, et al. Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group. J Clin Virol. 2018 May;102:42-49.
2. Rogan DT, et al. Impact of Rapid Molecular Respiratory Virus Testing on Real-Time Decision Making in a Pediatric Emergency Department. J Mol Diagn. 2017 May;19(3):460-467.
3. Liang SY, et al. Infection Prevention in the Emergency Department. Ann Emerg Med. 2014 Sep; 64(3): 299–313.

Infection Prevention

What could you prevent with the RIGHT results?

Deaths due to influenza increased by 116% last season (30,386 deaths)1

1. CDC. Weekly U.S. Influenza Surveillance Report. Accessed June 15, 2018. https://www.cdc.gov/flu/weekly/

Antimicrobial Stewardship

What would you do with the RIGHT results?

Children with acute respiratory infection:

27 of 100 have bacterial infections1
57 of 100 are treated with antimicrobials1


11.4M
Preventable Antimicrobial Prescriptions Annually (US)1

1. Havers F, et al. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Network Open. 2018;1(2): e180243.

×